Results Archives - Page 7 of 9 - World Asthma Foundation

March 28, 2012

Targacept slips on mixed results from drug studies – BusinessWeek

Targacept slips on mixed results from drug studies
BusinessWeek
Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for …
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of …MarketWatch (press release)
Targacept discontinues two clinical trials, reports success with a thirdWinston-Salem Journal (blog)
Asthma drug shows promise, diabetes study fails in Targacept phase 2 trialsMedCity News

all 41 news articles »

View full post on asthma – Google News

March 27, 2012

Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987 – RTT News

Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987
RTT News
(RTTNews) – Targacept Inc. (TRGT: News ) announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the US, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met …
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of …MarketWatch (press release)

all 6 news articles »

View full post on asthma – Google News

March 26, 2012

Relovair COPD and asthma filings on track despite more mixed trial results – The Pharma Letter

Proactive Investors USA & Canada

Relovair COPD and asthma filings on track despite more mixed trial results
The Pharma Letter
For asthma, the company plans to file for approval in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication. GSK is looking to replace its top-selling drug …
Relovair on track for filing in mid-2012, says GSKPMLiVE
GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, AsthmaGenetic Engineering News
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational …MarketWatch (press release)
Reuters –MedCity News –FierceBiotech
all 36 news articles »

View full post on asthma – Google News

February 25, 2012

Shock results of probe into Darlington child asthma deaths – The Advertiser Series

Shock results of probe into Darlington child asthma deaths
The Advertiser Series
A SHOCK report has discovered that nearly half of child asthma deaths in a North-East town occurred in youngsters with mild or moderate forms of the illness. The results of a survey of child asthma deaths in Darlington have prompted GPs, …

and more »

View full post on asthma – Google News

February 25, 2012

Shock results of probe into child asthma deaths – The Advertiser Series

Shock results of probe into child asthma deaths
The Advertiser Series
A SHOCK report has discovered that nearly half of child asthma deaths in a North-East town occurred in youngsters with mild or moderate forms of the illness. The results of a survey of child asthma deaths in Darlington have prompted GPs, …

View full post on asthma – Google News

February 25, 2012

Shock results of probe into Darlington child asthma deaths – The Northern Echo

Shock results of probe into Darlington child asthma deaths
The Northern Echo
A SHOCK report has discovered that nearly half of child asthma deaths in a North-East town occurred in youngsters with mild or moderate forms of the illness. The results of a survey of child asthma deaths in Darlington have prompted GPs, …

and more »

View full post on asthma – Google News

November 8, 2011

Halozyme Therapeutics Reports Third Quarter 2011 Financial Results – PR Newswire (press release)

Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
PR Newswire (press release)
Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology. HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of …
Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American …MarketWatch (press release)

all 27 news articles »

View full post on asthma – Google News

August 8, 2011

Array BioPharma Reports Results for the Fourth Quarter and Full Year of Fiscal … – MarketWatch (press release)

Array BioPharma Reports Results for the Fourth Quarter and Full Year of Fiscal …
MarketWatch (press release)
In addition, Array initiated new clinical trials for two proprietary anti-inflammatory drugs: ARRY-797 for pain and ARRY-502 for asthma. ARRY-797 is being tested in a 150-patient Phase 2 chronic pain trial in osteoarthritis (OA) patients with top-line …

and more »

View full post on asthma – Google News

June 15, 2011

Osteopathy for asthma? The results may take your breath away – The Guardian

Osteopathy for asthma? The results may take your breath away
The Guardian
Can osteopaths really cure asthma, and should newspapers be running uncritical promotional pieces for products claiming to treat serious conditions? Like chiropractic, osteopathy has a reasonable body of evidence backing its effectiveness in the short …

View full post on asthma – Google News

June 2, 2011